Literature DB >> 237800

Amelioration of hypoglycemia in a patient with malignant insulinoma during the development of the ectopic ACTH syndrome.

L Sadoff, J Gordon, S Goldman.   

Abstract

A patient with functioning islet cell carcinoma is described who had amelioration of her hypoglycemia during the development of ectopic ACTH syndrome. Moon facies and hyperkalemic metabolic acidosis were also present in this patient, features uncommonly seen in the actopic ACTH syndrome. At autopsy, she was found to have active tuberculosis. Prophylactic antituberculous therapy should be given to high-risk patients with the ectopic ACTH syndrome. High doses of ACTH may be palliative in refractory hypoglycemic states.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 237800     DOI: 10.2337/diab.24.6.600

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  4 in total

1.  Hyperinsulinemic hypoglycemia associated with ectopic Cushing's syndrome due to a pancreatic endocrine tumor in a Type 2 diabetes mellitus patient: clinical implications of a rare association.

Authors:  M Filippella; M V Davì; G Doveri; E Lillaz; A Ciccarelli; E Massimetti; M Toaiari; M Falconi; A Colao; A Faggiano
Journal:  J Endocrinol Invest       Date:  2010-04-12       Impact factor: 4.256

2.  Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma.

Authors:  Jan Novotny; Filip Janku; Pavel Mares; Lubos Petruzelka
Journal:  Support Care Cancer       Date:  2005-06-16       Impact factor: 3.603

3.  A case of insulin and ACTH co-secretion by a neuroendocrine tumour.

Authors:  S Solomou; R Khan; D Propper; D Berney; M Druce
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-02-01

Review 4.  Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.

Authors:  Johannes Hofland; Gregory Kaltsas; Wouter W de Herder
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.